Sisram Medical (HKG:1696) confirmed the commercialization of its aesthetic injection product DAXXIFY (RT002) in mainland China is progressing steadily, with regulatory, market access, and team-building preparations underway, according to a Monday Hong Kong bourse filing.
Shares of the medical device maker rose nearly 14% in Tuesday afternoon trade.
The company issued the statement as a clarification in response to continued market interest in the product's rollout.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.